Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3836 Target Snapshot

LIM domain kinase 1 · SINGLE PROTEIN · Homo sapiens

1,831Compounds
290Assays
16Approved Drugs
1,751.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P53667. Use UniProt P53667 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P53667 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats LIM domain kinase 1 as ChEMBL target CHEMBL3836, mapped to UniProt P53667. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
LIM domain kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3836
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53667
LIM domain kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether LIM domain kinase 1 is the right protein anchor across sources, using UniProt P53667 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLIM domain kinase 1
UniProt AccessionP53667
Component TypeProtein
Sequence Length647 aa

LIM domain kinase 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as LIM domain kinase 1, mapped to UniProt P53667. Sequence length is 647 aa.

Mapped IDP53667
Review nameLIM domain kinase 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

16
Approved
4
Phase III
15
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC50517.0
KI833.0
EC502.0
KD399.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3623439 9.52 IC50 0.3 Preclinical
CHEMBL5278261 9.52 IC50 0.3 Preclinical
CHEMBL570126 9.3 IC50 0.5 Preclinical
CHEMBL2070615 9.0 IC50 1.0 Preclinical
CHEMBL3623442 9.0 IC50 1.0 Preclinical
CHEMBL5275331 9.0 IC50 1.0 Preclinical
CHEMBL5169387 8.84 IC50 1.445 Preclinical
CHEMBL3218297 8.76 IC50 1.74 Preclinical
CHEMBL570116 8.7 IC50 1.995 Preclinical
CHEMBL388978 8.61 IC50 2.44 Preclinical
Distribution

pChEMBL Value Distribution

124
5.0
182
5.5
148
6.0
137
6.5
105
7.0
78
7.5
30
8.0
9
8.5
4
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPIVASERTIB
CHEMBL2325741
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
ENCORAFENIB
CHEMBL3301612
Approved 2018
DABRAFENIB
CHEMBL2028663
Approved 2013
REGORAFENIB
CHEMBL1946170
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
DASATINIB
CHEMBL5416410
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

290
Total Assays
399
Tested Compounds
2
Assay Types
Binding — 289 assays, 399 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 225 300 6.6
cell-based format 29 68 6.8
assay format 28 4 7.2
subcellular format 7 27 6.1
Functional — 1 assays, 346 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 346 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine